Relationship between Expression of Runt-related Transcription Factor 3 and Enhancer of zeste Homolog 2 Proteins and Sensitivity to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.
10.3881/j.issn.1000-503X.13969
- Author:
Ze-Long YUAN
1
;
Xue-Liang WU
2
;
Ming QU
2
;
Jun XUE
2
;
Lei HAN
2
;
Guang-Yuan SUN
2
Author Information
1. Department of Interventional Surgery,the First Affiliated Hospital of Hebei North University,Zhangjiakou,Hebei 075000,China.
2. Department of General Surgery,the First Affiliated Hospital of Hebei North University,Zhangjiakou,Hebei 075000,China.
- Publication Type:Journal Article
- Keywords:
Runt-related transcription factor 3;
XELOX;
advanced rectal cancer;
enhancer of zeste homolog 2;
neoadjuvant chemotherapy;
tumor regression grade
- MeSH:
Core Binding Factor Alpha 3 Subunit/genetics*;
Enhancer of Zeste Homolog 2 Protein/genetics*;
Humans;
Neoadjuvant Therapy;
Rectal Neoplasms/drug therapy*;
Transcription Factor 3
- From:
Acta Academiae Medicinae Sinicae
2021;43(6):856-864
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression and correlation of Runt-related transcription factor 3(RUNX3)and enhancer of zeste homolog 2(EZH2)in rectal cancer,and to reveal the relationship between the expression of RUNX3 and EZH2 and the sensitivity of XELOX regimen to neoadjuvant chemotherapy in locally advanced rectal cancer patients. Methods The carcinoma and paracancerous tissues of 31 patients with rectal adenocarcinoma and no preoperative antitumor therapy were selected as cancer group and paracancer group,respectively.The relative mRNA levels of RUNX3 and EZH2 in the two groups were measured by real-time quantitative reverse transcription-polymerase chain reaction,and the protein levels were determined by immunohistochemical assay.The expression of RUNX3 and EZH2 was compared between cancer tissue and paracancerous tissue.The pre-treatment wax blocks of 26 patients with locally advanced rectal cancer who received 3 cycles of XELOX regimen as neoadjuvant chemotherapy before surgery were selected as the pre-neoadjuvant therapy group,and the postoperative pathological wax blocks were selected as the post-neoadjuvant treatment group.Tumor regression grade(TRG)was determined to evaluate the efficacy of neoadjuvant therapy.Immunohistochemical assay was used to detect the protein levels of RUNX3 and EZH2 in the two groups,and then the relationship between the expression patterns of the two proteins and the efficacy of neoadjuvant chemotherapy was analyzed. Results Compared with paracancerous tissue,the cancer tissue showed down-regulated mRNA level and reduced positive protein expression rate of RUNX3,while up-regulated mRNA level(
